Vivos CEO Explains Breakthrough Sleep Apnea Tech and Path to Profitability | VVOS

Vivos Therapeutics (NASDAQ: VVOS) is redefining treatment for obstructive sleep apnea with a non-surgical oral appliance designed to remodel the airway and improve breathing. Unlike traditional CPAP machines, Vivos’ approach targets the root cause, with potential benefits extending beyond sleep apnea to broader chronic health conditions.

With over 75,000 patients treated and a rapidly expanding care model, the company is scaling through integrated sleep centers and increasing insurance coverage. Backed by a massive global market affecting over 1 billion people, Vivos is positioning itself for growth and targeting a transition to positive cash flow in the near term.

#VivosTherapeutics
#VVOS
#SleepApnea
#HealthcareInnovation
#MedicalDevices
#DigitalHealth
#AirwayHealth
#Wellness
#Biotech
#PatientCare
#MedicalTechnology
#ChronicDisease
#Innovation
#Healthcare
#NewsOut